Israeli imaging analysis software developer CathWorks said that results from a pivotal trial evaluating its FFRangio fractional flow reserve (FFR) analysis software will be presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in September in San Diego.
The trial, called FFRangio Accuracy vs. Standard FFR (FAST-FFR), was designed to evaluate the sensitivity and specificity of FFRangio compared with conventional invasive FFR at 10 cardiovascular centers around the world, according to CathWorks. Data from FAST-FFR will be presented in the late-breaking clinical science program on September 24.
In addition, the firm's system will be the focus of a TCT lunch presentation theater program, which will also be held on September 24, the company said.
